Sarepta Therapeutics
SRPT
319 hedge funds and large institutions have $1.67B invested in Sarepta Therapeutics in 2025 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 109 increasing their positions, 105 reducing their positions, and 106 closing their positions.
18% more capital invested
Capital invested by funds: $1.42B → $1.67B (+$258M)
4.61% more ownership
Funds ownership: 84.23% → 88.83% (+4.6%)
4% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 105
7% less call options, than puts
Call options by funds: $134M | Put options by funds: $144M
12% less funds holding
Funds holding: 362 → 319 (-43)
39% less first-time investments, than exits
New positions opened: 65 | Existing positions closed: 106
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$36.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.5M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$26.6M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$23.4M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$22.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$44.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$43.3M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$27.3M |
| 4 |
CC
Casdin Capital
New York
|
-$16.9M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$14.9M |
SRPT Hedge Fund Activity: Q3 2025 in Review
319 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2025, worth a combined $1.67B — up 18% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 106 funds closed out of SRPT and 65 opened new positions — a net loss of 41 holders — while 105 trimmed existing stakes and 109 added.
The largest buyer was Renaissance Technologies, adding an estimated $36.1M. The largest seller was D.E. Shaw & Co, cutting an estimated $44.1M.
- 319 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2025, down from 362 in Q2 2025.
- Funds reported $1.67B of Sarepta Therapeutics stock for Q3 2025, up 18% quarter-over-quarter.
- 65 funds opened new Sarepta Therapeutics positions in Q3 2025 and 106 closed out, a net change of -41 holders.
- The largest Sarepta Therapeutics buyer in Q3 2025 was Renaissance Technologies, an estimated $36.1M added.
- The largest Sarepta Therapeutics seller in Q3 2025 was D.E. Shaw & Co, an estimated $44.1M sold.
Based on aggregated 13F filings for Q3 2025.